

Special Issue

New and Special Subtypes of Breast Cancer

Message from the Guest Editors

In the past two decades, advances in understanding breast cancer (BC) biology have translated into improvements in patients' outcomes. Nowadays, we are witnessing the identification of new biological subtypes of BC, such as the HER2-low subtype. Modern antibody–drug conjugates (ADC) have been created and are tested in that condition; however, we are in the initial stages of the clinical understanding of these special subtypes. The research is also underway to assess the unique characteristics of ER-low BC. Scientific work on specific histological subtypes of breast cancer also brings new insights. In this Special Issue, “New and Special Subtypes of Breast Cancer”, we invite you to publish papers that focus on the latest achievements in the new BC subtypes including original as well as review articles. Research areas may include (but are not limited to) the following:

- The pathology of new/special BC subtypes;
- The clinical landscape of new/special BC subtypes;
- The challenges in new/special BC subtypes.

We look forward to receiving your contributions.

Guest Editors

Dr. Katarzyna Pogoda

Breast Cancer and Reconstructive Surgery Department, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Dr. Elżbieta Senkus

Department of Oncology and Radiotherapy, Medical University of Gdańsk, Smoluchowskiego 17, 80-214 Gdańsk, Poland

Deadline for manuscript submissions

closed (31 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/158606

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)